Arming Antibodies for Cancer Therapy: Transglutaminase-Mediated Toxin Conjugation
- Weitere Titel
-
Bewaffnung von Antikörpern für die Krebstherapie: Transglutaminase-vermittelte Toxin Konjugation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Darmstadt, Technische Universität Darmstadt, Dissertation, 2020
- Schlagwort
-
Immunoglobulins
Cancer--Treatment
Colmar
- Ereignis
-
Veröffentlichung
- (wo)
-
Darmstadt
- (wer)
-
Universitäts- und Landesbibliothek Darmstadt
- (wann)
-
2020
- Urheber
- Beteiligte Personen und Organisationen
- URN
-
urn:nbn:de:tuda-tuprints-114410
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Deweid, Ludwig Lukas
- Kolmar, Harald
- Süß, Beatrix
- Universitäts- und Landesbibliothek Darmstadt
Entstanden
- 2020
Ähnliche Objekte (12)
Tag-free, specific conjugation of glycosylated IgG1 antibodies using microbial transglutaminase
Charakterisierung von Zellwandproteinen des Transglutaminase-Produzenten Streptomyces mobaraensis
Discovery and Characterization of Allosteric Antibodies
Anti-idiotype antibodies for biomedical applications
Biopolymeric scaffold to achieve high drug-to-antibody ratios using site specific conjugation strategies
Functionality-Enhanced Antibodies for Precision Cancer Therapy
Intein mediated high throughput screening for bispecific antibodies
Merge Two into One: Multispecific Symmetric Antibodies for Cancer Immunotherapy
Better safe than sorry: dual targeting antibodies for cancer immunotherapy
Development of Innovative Bioconjugation Strategies for the Generation of Bi-Specific Antibodies Enabling Targeted Protein Degradation
Modulation of the FKBP51 structure by protein engineering and isolation of conformation-locking antibodies and affibodies
Validation and characterization of monoclonal antibodies to target cancer stem cells and to develop new anti-cancer therapies
Tag-free, specific conjugation of glycosylated IgG1 antibodies using microbial transglutaminase
Charakterisierung von Zellwandproteinen des Transglutaminase-Produzenten Streptomyces mobaraensis
Discovery and Characterization of Allosteric Antibodies
Anti-idiotype antibodies for biomedical applications
Biopolymeric scaffold to achieve high drug-to-antibody ratios using site specific conjugation strategies
Functionality-Enhanced Antibodies for Precision Cancer Therapy
Intein mediated high throughput screening for bispecific antibodies
Merge Two into One: Multispecific Symmetric Antibodies for Cancer Immunotherapy
Better safe than sorry: dual targeting antibodies for cancer immunotherapy
Development of Innovative Bioconjugation Strategies for the Generation of Bi-Specific Antibodies Enabling Targeted Protein Degradation
Modulation of the FKBP51 structure by protein engineering and isolation of conformation-locking antibodies and affibodies
Validation and characterization of monoclonal antibodies to target cancer stem cells and to develop new anti-cancer therapies
Tag-free, specific conjugation of glycosylated IgG1 antibodies using microbial transglutaminase
Charakterisierung von Zellwandproteinen des Transglutaminase-Produzenten Streptomyces mobaraensis
Discovery and Characterization of Allosteric Antibodies
Anti-idiotype antibodies for biomedical applications
Biopolymeric scaffold to achieve high drug-to-antibody ratios using site specific conjugation strategies
Functionality-Enhanced Antibodies for Precision Cancer Therapy
Intein mediated high throughput screening for bispecific antibodies
Merge Two into One: Multispecific Symmetric Antibodies for Cancer Immunotherapy
Better safe than sorry: dual targeting antibodies for cancer immunotherapy
Development of Innovative Bioconjugation Strategies for the Generation of Bi-Specific Antibodies Enabling Targeted Protein Degradation
Modulation of the FKBP51 structure by protein engineering and isolation of conformation-locking antibodies and affibodies